Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05579132 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT05579132 · ClinicalTrials.gov record · last posted 2026-08-20

A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)

StatusRecruiting
PhasePhase 1/2
Started2022-11-01
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
Researchers are looking for new ways to treat people with a type of blood cancer called precursor B-cell Acute Lymphoblastic Leukemia (B-ALL) that is relapsed- the cancer has come back after treatment, or refractory - the current treatment has stopped working to slow or stop cancer growth. This study will have two parts. In the first part (dose escalation phase) the goal is to learn about the safety of a study treatment, MK-1045, and to find the best dose level of MK-1045 that is tolerated and may work to treat B-ALL. In the second part (Phase II) researchers want to learn how well MK-1045 works to treat B-ALL.

Protocol amendment history 2 changes detected by DataLookout

2026-08-21
Primary completion pushed: 2028-06-30 → 2028-12-31
2026-08-21
Completion pushed: 2028-06-30 → 2028-12-31
Trial Details
NCT Number NCT05579132
Lead Sponsor MSD R&D (China) Co., Ltd.
Conditions Acute Lymphoblastic Leukemia
Enrollment 203 participants
Start Date 2022-11-01
Primary Completion 2028-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-20